G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.275 GBX -9%
Market Cap: 12.4m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genedrive PLC
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Current Portion of Long-Term Debt
ÂŁ129k
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Current Portion of Long-Term Debt
ÂŁ4.3m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Current Portion of Long-Term Debt
ÂŁ146k
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Current Portion of Long-Term Debt
ÂŁ1.6m
CAGR 3-Years
-7%
CAGR 5-Years
170%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Current Portion of Long-Term Debt
ÂŁ253k
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Current Portion of Long-Term Debt
ÂŁ1.4m
CAGR 3-Years
-12%
CAGR 5-Years
48%
CAGR 10-Years
24%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
12.4m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.42 GBX
Overvaluation 82%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
129k GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Current Portion of Long-Term Debt amounts to 129k GBP.

What is Genedrive PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
52%

Over the last year, the Current Portion of Long-Term Debt growth was -42%. The average annual Current Portion of Long-Term Debt growth rates for Genedrive PLC have been 52% over the past three years .

Back to Top